What is HC Wainwright’s Forecast for IPSEN FY2026 Earnings?

IPSEN (OTCMKTS:IPSEY) – Equities researchers at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for IPSEN in a report issued on Friday, June 5th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of $3.49 for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IPSEN’s current full-year earnings is $4.05 per share. HC Wainwright also issued estimates for IPSEN’s FY2027 earnings at $3.92 EPS.

Several other research analysts have also recently issued reports on IPSEY. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold”.

IPSEN Price Performance

Shares of OTCMKTS:IPSEY opened at $46.75 on Tuesday. The stock’s 50-day simple moving average is $47.87 and its two-hundred day simple moving average is $42.78. IPSEN has a 52-week low of $28.66 and a 52-week high of $51.10.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).